查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1284116

奈米醫藥的全球市場的評估:各奈米分子類型，各用途，各適應症，各地區，機會，預測(2016年～2030年)

Global Nanomedicine Market Assessment, By Nanomolecule Type, By Application, By Disease Indication, By Region, Opportunities, and Forecast 2016-2030F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 105 Pages | 商品交期: 3-5個工作天內

價格

全球奈米醫藥的市場規模，從2022年的1,684億美元到2030年預計達到3,197億2,000萬美元，2023年～2030年的預測期間以8.34％的年複合成長率成長。新的藥物輸送技術的出現，及許多醫療用途中奈米醫藥的優點，政府的支援和融資增加，促進市場擴大。

本報告提供全球奈米醫藥市場相關調查分析，市場規模與預測，市場動態，主要企業的形勢及預測等資訊。

目錄

第1章 調查手法

第2章 計劃的範圍和定義

第3章 COVID-19的影響

第4章 俄羅斯、烏克蘭戰爭的影響

第5章 摘要整理

第6章 全球奈米醫藥市場預測(2016年～2030年)

  • 市場規模與預測
    • 金額
    • 數量
  • 各奈米分子類型
    • 奈米粒子
    • 奈米殼
    • 奈米設備
    • 奈米碳管
  • 各用途
    • 藥物輸送
    • 疫苗
    • 影像診斷
    • 再生醫療
    • 其他
  • 各適應症
    • 腫瘤性疾病
    • 感染疾病
    • 整形外科疾病
    • 心血管疾病
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲
  • 市場佔有率:各企業(2022年)

第7章 全球奈米醫藥市場預測:各地區(2016年～2030年)

  • 北美
    • 各奈米分子類型
    • 各用途
    • 各適應症
    • 各地區
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 丹麥
    • 土耳其
    • 西班牙
  • 南美
    • 巴西
    • 阿根廷
    • 哥倫比亞
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳洲
    • 越南
    • 韓國
    • 馬來西亞
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 以色列
    • 科威特

第8章 市場製圖(2022年)

  • 各奈米分子類型
  • 各用途
  • 各適應症
  • 各地區

第9章 宏觀環境和產業結構

  • 供需的分析
  • 進出口的分析 - 數量和金額
  • 支援/價值鏈分析
  • PESTEL分析
  • 波特的五力分析

第10章 市場動態

  • 成長促進因素
  • 阻礙成長的要素(課題與阻礙因素)

第11章 法律規範和革新

  • 臨床試驗
  • 專利形勢
  • FDA的認證
  • 革新/新興技術

第12章 主要企業形勢

  • 市場領導者前五名公司的競爭矩陣
  • 市場領導者前五名公司的市場收益分析(2022年)
  • 如果合併和收購/合資企業(如果適用)
  • SWOT分析(5家市場參與企業)

第13章 價格分析

第14章 案例研究

第15章 主要企業預測

  • Pfizer Inc.
  • Sanofi S.A.
  • Amgen Inc
  • Moderna, Inc
  • Novo Nordisk A/S
  • Celgene Corporation
  • Teva
  • Pharmaceutical Industries Ltd.
  • Abbott Laboratories
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc

第16章 策略性推薦事項

第17章 關於本公司、免責聲明

Product Code: MX10084

Global Nanomedicine Market size was valued at USD 168.4 billion in 2022 which is expected to reach USD 319.72 billion in 2030 growing with a CAGR of 8.34% for the forecast period between 2023 and 2030.

Emerging new drug delivery technologies, the benefits of nanomedicine in numerous healthcare applications, and an increase in government support and financing are driving market expansion. Furthermore, the growing need for safe and cost-effective medicines contributes to market expansion.

Nanomedicine enhances the delivery of medicine by manipulating materials at the nanoscale. Therefore, nanomedicine has made it possible to treat a variety of diseases. As several products are in the development stage, nanomedicine is now in its infancy. The developing technologies for drug delivery are important elements that are anticipated to boost the growth of the nanomedicine market in the forecast period. However, the industry is projected to be hampered by the lengthy clearance procedure and the complications associated with the use of nanomedicines.

Advancement in Medical Technology

The invention of nanoscale medication delivery devices has been one of the most significant advances in nanomedicine. These methods employ nanoparticles to deliver medications directly to specific cells or tissues in the body, lowering the risk of adverse effects and increasing therapy efficacy. These drug delivery systems have the potential to transform the treatment of numerous illnesses, including cancer, diabetes, and cardiovascular disease.

Nanosensor is another significant milestone in nanomedicine which can detect and measure particular molecules or biomarkers in the body, offering vital diagnostic information for a variety of disorders. Nanosensors offer the potential to enhance early identification and treatment of numerous diseases by monitoring anything from blood glucose levels in diabetic patients to cancer indicators in cancer patients.

Increasing Awareness of Nanomedicines Among General Population

The worldwide nanomedicine market is primarily driven by rising healthcare awareness. People are more inclined to seek out medical treatment and services as they grow more conscious of the value of their health and wellness. With increased awareness of the potential benefits of nanomedicine, there has been a substantial surge in research and development activity in this sector. This has resulted in the creation of various innovative nanomedicine products and therapies, which are propelling the industry forward. Furthermore, the frequency of chronic illnesses including cancer, diabetes, and cardiovascular disorders is rising, which has increased demand for nanomedicine. Nanomedicine has emerged as a promising alternative for the treatment of various disorders due to its capacity to target certain cells and tissues in the body.

Government Initiatives

Government agencies are probably going to enhance their R&D spending, creating appealing chances for market development. Massive capital-intensive projects can be accelerated with the help of government funding. To improve nanoscale engineering, science, and technology, the National Science Foundation announced that it will spend a total of USD 84 million over the course of five years to re-establish the National Nanotechnology Coordinated Infrastructure. Additionally, the Canadian government funds research in the fields of nanomedicine and regenerative medicine at the Canadian Institutes of Health Research (CIHR) and the Canadian Space Agency (CSA). As a result, it will fuel the expansion of the nanomedicine sector in the upcoming years.

Innovations in Nanomedicine

It is projected that the development of innovative nanoscience-based treatments will be actively pursued by reputable pharmaceutical firms, which will have an impact on the market for nanomedicine. For instance, in May 2022, the Marble Centre for Cancer Nanomedicine, in association with Alloy Therapeutics, FUJIFILM Holdings America Corporation, Sanofi, and Danaher Corporation, introduced an affiliate programme.

The programme intends to promote industry-academia research partnerships to support ground-breaking breakthroughs in the nanomedicine sector. Additionally, the expansion of the nanomedicine sector is anticipated to be aided by breakthroughs in nanotechnology and its growing applications in preventative interventions, early illness detection, prevention of chronic as well as acute diseases, and prophylaxis of acute as well as chronic disorders.

Impact of COVID-19

The global market for nanomedicine has been significantly impacted by the COVID-19 pandemic. While the pandemic brought difficulties for the sector, it also offered chances for development and innovation.

The pandemic impacted the nanomedicine supply chain by creating delays and shortages. The pandemic expedited nanomedicine research and development efforts, with many firms and researchers shifting their emphasis to finding answers to the virus. Nanomedicine has been at the forefront of COVID-19 therapy development, such as the utilisation of nanoparticles for medication delivery and the creation of nanosensors for viral detection.

Key Players Landscape and Outlook

According to a study article titled "Recent Advances in Nanomaterials Development for Nanomedicine and Cancer" that was published in July 2021, Point-of-care and extremely sensitive techniques of cancer diagnosis have also been developed using a lot of nano-based materials and technologies. As a result, the market is expanding due to developments in nanomedicine for the diagnosis of cancer.

In January 2022, Pfizer and Acuitas Therapeutics announced their agreement for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics.

Market Xcel's reports answer the following questions:

What is the current and future market size of the product/service in question globally or specific to different countries?

How are the markets divided into different product/service segments and the market size and growth of each segment?

What is the market potential of different product segments and their invest case?

How are the markets predicted to develop in the future and what factors will drive or inhibit growth?

What is the business environment and regulatory landscape specific to the product/service?

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19

4. Impact of Russia-Ukraine War

5. Executive Summary

6. Global Nanomedicine Market Outlook, 2016-2030F

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
    • 6.1.2. By Volume
  • 6.2. By Nanomolecule Type
    • 6.2.1. Nanoparticles
      • 6.2.1.1. Polymer-Based
      • 6.2.1.2. Lipid-Based
      • 6.2.1.3. Nanocrystals
      • 6.2.1.4. Inorganic
      • 6.2.1.5. Others
    • 6.2.2. Nanoshells
    • 6.2.3. Nanodevices
    • 6.2.4. Nanotubes
  • 6.3. By Applications
    • 6.3.1. Drug Delivery
    • 6.3.2. Vaccines
    • 6.3.3. Diagnostic Imaging
    • 6.3.4. Regenerative Medicine
    • 6.3.5. Others
  • 6.4. By Disease Indication
    • 6.4.1. Oncological Diseases
    • 6.4.2. Infectious Diseases
    • 6.4.3. Orthopedic Disorders
    • 6.4.4. Cardiovascular Diseases
    • 6.4.5. Others
  • 6.5. By Region
    • 6.5.1. North America
    • 6.5.2. Europe
    • 6.5.3. South America
    • 6.5.4. Asia-Pacific
    • 6.5.5. Middle East & Africa
  • 6.6. By Company Market Share (%), 2022

7. Global Nanomedicine Market Outlook, By Region, 2016-2030F

  • 7.1. North America*
    • 7.1.1. By Nanomolecule Type
      • 7.1.1.1.1. Nanoparticles
      • 7.1.1.1.1.1. Polymer-Based
      • 7.1.1.1.1.2. Lipid-Based
      • 7.1.1.1.1.3. Nanocrystals
      • 7.1.1.1.1.4. Inorganic
      • 7.1.1.1.1.5. Others
      • 7.1.1.1.2. Nanoshells
      • 7.1.1.1.3. Nanodevices
      • 7.1.1.1.4. Nanotubes
    • 7.1.2. By Applications
      • 7.1.2.1.1. Drug Delivery
      • 7.1.2.1.2. Vaccines
      • 7.1.2.1.3. Diagnostic Imaging
      • 7.1.2.1.4. Regenerative Medicine
      • 7.1.2.1.5. Others
    • 7.1.3. By Disease Indication
      • 7.1.3.1.1. Oncological Diseases
      • 7.1.3.1.2. Infectious Diseases
      • 7.1.3.1.3. Orthopedic Disorders
      • 7.1.3.1.4. Cardiovascular Diseases
      • 7.1.3.1.5. Others
    • 7.1.4. By Region
      • 7.1.4.1.1. North America
      • 7.1.4.1.2. Europe
      • 7.1.4.1.3. South America
      • 7.1.4.1.4. Asia-Pacific
      • 7.1.4.1.5. Middle East & Africa
    • 7.1.5. United States*
      • 7.1.5.1. By Nanomolecule Type
      • 7.1.5.1.1. Nanoparticles
      • 7.1.5.1.1.1. Polymer-Based
      • 7.1.5.1.1.2. Lipid-Based
      • 7.1.5.1.1.3. Nanocrystals
      • 7.1.5.1.1.4. Inorganic
      • 7.1.5.1.1.5. Others
      • 7.1.5.1.2. Nanoshells
      • 7.1.5.1.3. Nanodevices
      • 7.1.5.1.4. Nanotubes
      • 7.1.5.2. By Applications
      • 7.1.5.2.1. Drug Delivery
      • 7.1.5.2.2. Vaccines
      • 7.1.5.2.3. Diagnostic Imaging
      • 7.1.5.2.4. Regenerative Medicine
      • 7.1.5.2.5. Others
      • 7.1.5.3. By Disease Indication
      • 7.1.5.3.1. Oncological Diseases
      • 7.1.5.3.2. Infectious Diseases
      • 7.1.5.3.3. Orthopedic Disorders
      • 7.1.5.3.4. Cardiovascular Diseases
      • 7.1.5.3.5. Others
    • 7.1.6. Canada
    • 7.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 7.2. Europe
    • 7.2.1. Germany
    • 7.2.2. France
    • 7.2.3. Italy
    • 7.2.4. United Kingdom
    • 7.2.5. Denmark
    • 7.2.6. Turkey
    • 7.2.7. Spain
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Colombia
  • 7.4. Asia-Pacific
    • 7.4.1. India
    • 7.4.2. China
    • 7.4.3. Japan
    • 7.4.4. Australia
    • 7.4.5. Vietnam
    • 7.4.6. South Korea
    • 7.4.7. Malaysia
  • 7.5. Middle East & Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. South Africa
    • 7.5.4. Israel
    • 7.5.5. Kuwait

8. Market Mapping, 2022

  • 8.1. By Nanomolecule Type
  • 8.2. By Application
  • 8.3. By Disease Indication
  • 8.4. By Region

9. Macro Environment and Industry Structure

  • 9.1. Supply Demand Analysis
  • 9.2. Import Export Analysis - Volume and Value
  • 9.3. Supply/Value Chain Analysis
  • 9.4. PESTEL Analysis
    • 9.4.1. Political Factors
    • 9.4.2. Economic System
    • 9.4.3. Social Implications
    • 9.4.4. Technological Advancements
    • 9.4.5. Environmental Impacts
    • 9.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 9.5. Porter's Five Forces Analysis
    • 9.5.1. Supplier Power
    • 9.5.2. Buyer Power
    • 9.5.3. Substitution Threat
    • 9.5.4. Threat from New Entrant
    • 9.5.5. Competitive Rivalry

10. Market Dynamics

  • 10.1. Growth Drivers
  • 10.2. Growth Inhibitors (Challenges, Restraints)

11. Regulatory Framework and Innovation

  • 11.1. Clinical Trials
  • 11.2. Patent Landscape
  • 11.3. FDA Approvals
  • 11.4. Innovations/Emerging Technologies

12. Key Players Landscape

  • 12.1. Competition Matrix of Top Five Market Leaders
  • 12.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 12.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 12.4. SWOT Analysis (For Five Market Players)

13. Pricing Analysis

14. Case Studies

15. Key Players Outlook

  • 15.1. Pfizer Inc.
    • 15.1.1. Company Details
    • 15.1.2. Key Management Personnel
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As reported)
    • 15.1.5. Key Market Focus & Geographical Presence
    • 15.1.6. Recent Developments
  • 15.2. Sanofi S.A.
  • 15.3. Amgen Inc
  • 15.4. Moderna, Inc
  • 15.5. Novo Nordisk A/S
  • 15.6. Celgene Corporation
  • 15.7. Teva
  • 15.8. Pharmaceutical Industries Ltd.
  • 15.9. Abbott Laboratories
  • 15.10. Johnson & Johnson Services, Inc.
  • 15.11. Merck & Co., Inc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

16. Strategic Recommendations

17. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Types from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 3. Global Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 4. Global Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 5. Global Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 6. Global Nanomedicine Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 7. North America Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 8. North America Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 9. North America Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 10. North America Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 11. North America Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 12. North America Nanomedicine Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 13. United States Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 14. United States Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 15. United States Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 16. United States Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 17. United States Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 18. Canada Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 19. Canada Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 20. Canada Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 21. Canada Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 22. Canada Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 23. Mexico Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 24. Mexico Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 25. Mexico Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 26. Mexico Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 27. Mexico Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 28. Europe Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 29. Europe Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 30. Europe Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 31. Europe Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 32. Europe Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 33. Europe Nanomedicine Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 34. Germany Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 35. Germany Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 36. Germany Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 37. Germany Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 38. Germany Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 39. France Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 40. France Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 41. France Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 42. France Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 43. France Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 44. Italy Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 45. Italy Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 46. Italy Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 47. Italy Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 48. Italy Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 49. United Kingdom Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 50. United Kingdom Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 51. United Kingdom Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 52. United Kingdom Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 53. United Kingdom Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 54. Denmark Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 55. Denmark Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 56. Denmark Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 57. Denmark Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 58. Denmark Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 59. Turkey Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 60. Turkey Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 61. Turkey Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 62. Turkey Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 63. Turkey Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 64. Spain Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 65. Spain Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 66. Spain Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 67. Spain Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 68. Spain Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 69. South America Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 70. South America Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 71. South America Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 72. South America Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 73. South America Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 74. South America Nanomedicine Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 75. Brazil Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 76. Brazil Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 77. Brazil Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 78. Brazil Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 79. Brazil Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 80. Argentina Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 81. Argentina Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 82. Argentina Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 83. Argentina Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 84. Argentina Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 85. Colombia Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 86. Colombia Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 87. Colombia Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 88. Colombia Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 89. Colombia Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 90. Asia-Pacific Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 91. Asia-Pacific Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 92. Asia-Pacific Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 93. Asia-Pacific Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 94. Asia-Pacific Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 95. Asia-Pacific Nanomedicine Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 96. India Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 97. India Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 98. India Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 99. India Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 100. India Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 101. China Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 102. China Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 103. China Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 104. China Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 105. China Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 106. Japan Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 107. Japan Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 108. Japan Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 109. Japan Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 110. Japan Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 111. Australia Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 112. Australia Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 113. Australia Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 114. Australia Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 115. Australia Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 116. Vietnam Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 117. Vietnam Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 118. Vietnam Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 119. Vietnam Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 120. Vietnam Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 121. South Korea Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 122. South Korea Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 123. South Korea Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 124. South Korea Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 125. South Korea Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 126. Malaysia Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 127. Malaysia Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 128. Malaysia Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 129. Malaysia Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 130. Malaysia Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 131. Middle East & Africa Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 132. Middle East & Africa Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 133. Middle East & Africa Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 134. Middle East & Africa Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 135. Middle East & Africa Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 136. Middle East & Africa Nanomedicine Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 137. Saudi Arabia Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 138. Saudi Arabia Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 139. Saudi Arabia Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 140. Saudi Arabia Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 141. Saudi Arabia Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 142. UAE Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 143. UAE Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 144. UAE Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 145. UAE Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 146. UAE Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 147. South Africa Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 148. South Africa Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 149. South Africa Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 150. South Africa Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 151. South Africa Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 152. Israel Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 153. Israel Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 154. Israel Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 155. Israel Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 156. Israel Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 157. Kuwait Nanomedicine Market, By Value, In USD Billion, 2016-2030F
  • Figure 158. Kuwait Nanomedicine Market, By Volume, In Tons, 2016-2030F
  • Figure 159. Kuwait Nanomedicine Market Share, By Nanomolecule Type, In USD Billion, 2016-2030F
  • Figure 160. Kuwait Nanomedicine Market Share, By Application, In USD Billion, 2016-2030F
  • Figure 161. Kuwait Nanomedicine Market Share, By Disease Indication, In USD Billion, 2016-2030F
  • Figure 162. By Nanomolecule Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 163. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 164. By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022